Telix Spins Off Rhine Pharma to Broaden Global Radiopharmaceutical Reach
Shots:
- Telix Pharmaceuticals will spin off Rhine Pharma to make it an independent entity, broadening global reach to radiopharmaceuticals for cancer imaging & treatment using two isotopes, technetium-99m (Tc-99m) & rhenium-188 (Re-188)
- Rhine Pharma was created under a collaboration between Telix and Heidelberg University Hospital for developing a PSMA-targeting small molecule labelled with 99mTc for SPECT imaging and 188Re for radioligand therapy
- RHN001 was developed under the collaboration. Rhine Pharma is conducting P-I/IIa (RHINO) trial to assess the safety & efficacy of 99mTc-RHN001 for imaging & 188Re-RHN001 for therapy to treat advanced prostate cancer
Ref: Telix | Image: Telix
Related News:- Telix to Expand its US Operations Through the Acquisition of RLS Radiopharmacies
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
